MannKind has enrolled the first patient in INHALE-1ST, a U.S. multi-center, single-arm study evaluating Afrezza (inhaled human insulin) initiated shortly after type 1 diabetes diagnosis in youth aged 10 to under 18. About 100 participants across roughly 10 sites will use Afrezza for prandial insulin alongside once-daily injected basal insulin. The 13-week main phase is followed by an optional 26-week extension. The primary endpoint is the proportion of participants achieving a CGM-measured time in range (70–180 mg/dL) of at least 70% during the 14 days prior to the week-13 visit (NCT07224321).
The trial is operationally notable for where it aims to intervene: immediately post-diagnosis, during a period when families and care teams set long-term habits and technology pathways. Led by the Jaeb Center for Health Research, with first enrollment at the Barbara Davis Center in Colorado, the study also collects participant and caregiver-reported outcomes to quantify treatment burden and satisfaction when inhaled insulin replaces most mealtime injections. Although non-comparative, the design aligns with current practice patterns that rely on CGM-derived endpoints and experience measures to support adoption decisions, especially in pediatrics.
Strategically, MannKind is running INHALE-1ST in parallel with FDA review of its pediatric sBLA for Afrezza, which has a May 29, 2026 PDUFA date. If approved, Afrezza would become the first needle-free insulin option for pediatric patients, positioning the company to target an initiation setting where the barrier to change is often behavioral rather than purely clinical. A single-arm, short-duration study is unlikely to move regulators, but it can equip clinicians, payers, and care teams with early, diagnosis-adjacent evidence on glycemic control and usability—data types that often determine uptake in pediatric endocrinology more than modest A1c deltas. It also signals MannKind’s intent to frame Afrezza not as a late-stage optimization tool but as part of first-line workflows.
The move also exposes Afrezza’s operational realities. Baseline spirometry and lung history are required before initiation, and pediatric asthma prevalence will narrow the eligible population. Sites must be ready to perform respiratory assessments, manage inhaler training, and integrate school-based care plans—capabilities unevenly distributed across centers. The endpoint threshold of time in range ≥70% at week 13 sits within reach for many newly diagnosed youth due to honeymoon physiology, which could both lift headline success rates and complicate interpretation without a comparator. Meanwhile, the pediatric market is increasingly oriented around automated insulin delivery; inhaled prandial insulin must demonstrate clear advantages in ease, flexibility, or hypoglycemia risk to justify workflows that diverge from pump-based algorithms.
For sponsors and CROs, INHALE-1ST reflects several converging trends: deeper reliance on CGM endpoints, experience metrics as decision drivers, and small, operationally pragmatic studies designed to seed post-approval adoption. For sites, the study’s requirements underscore a growing intersection between metabolic trials and pulmonary screening infrastructure, and the need to resource device training at diagnosis. For payers, any post-approval positioning will hinge on demonstrable reductions in injection burden, school-day dosing logistics, and real-world glycemic control without added safety surveillance complexity.
Key watch items are the FDA’s stance on pediatric labeling, especially any spirometry monitoring requirements that could burden routine care; how MannKind plans to position Afrezza relative to hybrid closed-loop systems; and whether the study’s patient- and caregiver-reported outcomes translate into payer and guideline traction. If approval arrives on time, launch readiness will depend on site-level pulmonary testing capacity, standardized initiation pathways at diagnosis, and school integration—practicalities that will determine whether inhaled mealtime insulin becomes a niche alternative or a true first-visit option in pediatric diabetes care.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
